A Randomized, Double-Blinded, Placebo-Controlled Trial Comparing Antiretroviral Intensification With Maraviroc and Dolutegravir With No Intensification or Intensification With Dolutegravir Alone for the Treatment of Cognitive Impairment in HIV

Trial Profile

A Randomized, Double-Blinded, Placebo-Controlled Trial Comparing Antiretroviral Intensification With Maraviroc and Dolutegravir With No Intensification or Intensification With Dolutegravir Alone for the Treatment of Cognitive Impairment in HIV

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Maraviroc (Primary) ; Dolutegravir
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms InMIND
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 23 Sep 2016 Planned primary completion date changed from 1 Dec 2018 to 1 Oct 2018.
    • 23 Sep 2016 Planned primary completion date changed from 1 Dec 2018 to 1 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top